Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Moxetumomab Pasudotox in HCL

June 18th 2019

Non-Chemotherapy Agents & Anti-CD22 in HCL Treatment

June 18th 2019

BRAF/MEK Inhibition in HCL Management

June 18th 2019

The Use of Splenectomy in HCL Treatment

June 18th 2019

Treating Relapsed/Refractory or Progressive HCL

June 18th 2019

The Role of MRD in Treatment of HCL

June 18th 2019

Concurrent vs Sequential Rituximab in HCL

June 18th 2019

HCL Combination Therapy: Rituximab and Purine Analog

June 18th 2019

Indicators Prompting Treatment of HCL

June 18th 2019

First-Line Therapy Options in Hairy Cell Leukemia

June 18th 2019

Parting Advice on Hairy Cell Leukemia Management

June 18th 2019

Hairy Cell Leukemia: Unmet Needs and Combination Strategies

June 18th 2019

Moxetumomab Pasudotox for HCL: Managing Side Effects

June 18th 2019

Anti-CD22 Therapy in HCL: Moxetumomab Pasudotox

June 18th 2019

Monitoring Response & Initiating Second-Line Therapy in HCL

June 18th 2019

Approaches to Frontline Therapy in HCL

June 18th 2019

A Differential Diagnosis of Hairy Cell Leukemia

June 18th 2019

Hairy Cell Leukemia: Incidence and Presentation

June 18th 2019

Dr. O'Brien on the Phase III ASCEND Trial in CLL

June 16th 2019

Susan M. O’Brien, MD, associate director for Clinical Services, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, discusses the phase III ASCEND trial in chronic lymphocytic leukemia.

New Macrophage Immune Checkpoint Strategy Shows Promise in AML and MDS

June 16th 2019

Hu5F9-G4 (5F9), a first-in-class antibody targeting CD47, used as monotherapy or in combination with standard azacitidine was well tolerated and provided deep and durable responses in patients with acute myeloid leukemia or myelodysplastic syndrome, according to findings from a phase IB study presented at the 2019 European Hematology Association Congress.